Interventions for vitiligo

Whitton, Maxine E; Pinart, Mariona; Batchelor, Jonathan; Leonardi‐Bee, Jo; González, Urbà; Jiyad, Zainab; Eleftheriadou, Viktoria; Ezzedine, Khaled

doi:10.1002/14651858.cd003263.pub5

Cited by 115 publications

(50 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 The disease can affect individuals of different ages, but it generally begins at around 22 years of age in the USA, 25 in England, and 24 in Brazil. 1,3 Vitiligo entails a considerable psychological impact as well as an impact on the quality of life of the affected individuals, which can result in relationship problems, low self-esteem, high levels of anxiety, and even depression.…”

Section: Introductionmentioning

confidence: 99%

“…Nearly one-third of the patients with vitiligo have a family history of the disease, and genetic studies have demonstrated an association with other auto-immune diseases, such as thyroid disease, diabetes, pernicious anemia, Addison's disease, rheumatoid arthritis, among others. 2,8 The association between vitiligo and the haplotypes of human leukocyte antigens (HLA) also appears to be important in the pathogenesis of the disease in the populations of Brazil and the world. 9 Among the diverse and complex pathogenic mechanisms involved in the development and clinical evolution of vitiligo are biochemical alterations, neural mechanisms, and intrinsic defects in the adherence and survival of melanocytes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo

Ramos

Ramos³

2017

An. Bras. Dermatol.

View full text Add to dashboard Cite

BackgroundVitiligo is a chronic disease characterized by the appearance of achromic macules caused by melanocyte destruction. Surgical treatments with melanocyte transplantation can be used for stable vitiligo cases. ObjectivesTo evaluate treatment response to the autologous transplantation of noncultured epidermal cell suspension in patients with stable vitiligo.MethodsCase series study in patients with stable vitiligo submitted to noncultured epidermal cell suspension transplantation and evaluated at least once, between 3 and 6 months after the procedure, to observe repigmentation and possible adverse effects. The maximum follow-up period for some patients was 24 months.ResultsOf the 20 patients who underwent 24 procedures, 25% showed an excellent rate of repigmentation, 50% good repigmentation, 15% regular, and 10% poor response. The best results were observed in face and neck lesions, while the worst in extremity lesions (88% and 33% of satisfactory responses, respectively). Patients with segmental vitiligo had a better response (84%) compared to non-segmental ones (63%). As side effects were observed hyperpigmentation of the treated area and the appearance of Koebner phenomenon in the donor area.Study limitationsSome limitations of the study included the small number of patients, a subjective evaluation, and the lack of long-term follow-up on the results. CONCLUSION: Noncultured epidermal cell suspension transplantation is efficient and well tolerated for stable vitiligo treatment, especially for segmental vitiligo on the face and neck.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo

Ramos

Ramos³

2017

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…In addition to the review commissioned as part of this Programme Grant, we have also undertaken a further update of the Cochrane review 432 and the results should be available in 2014. We have identified a further 39 RCTs for this latest update, giving a total of 96 RCTs to be included in the review.…”

Section: Update the Review Beyond 2010mentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

Self Cite

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

“…Vitiligo is an intriguing depigmentary disorder affecting approximately 0.5% to 1% of the world population [1]. It has significant effects on quality of life and remains a persistent burden on patients.…”

Section: Introductionmentioning

confidence: 99%

“…In this circumstance, topical CIs provide a favorable alternative. A recent meta-analysis on the effect of topical CIs as monotherapy or combined with phototherapy for vitiligo treatment showed that CIs resulted in cosmetically acceptable repigmentation, particularly on the face and neck [181213]. Moreover, 1% pimecrolimus cream has even been shown to be of equal efficacy to 0.05% clobetasol propionate ointment [14].…”

Section: Introductionmentioning

confidence: 99%

Pimecrolimus increases the melanogenesis and migration of melanocytes in vitro

Chen

Tan

et al. 2017

Korean J Physiol Pharmacol

View full text Add to dashboard Cite

Vitiligo is an intriguing depigmentary disorder and is notoriously difficult to be treated. The ultimate goal of vitiligo treatment is to replenish the lost melanocytes by immigration from hair follicle and to restore the normal function of melanogenesis by residual melanocytes. There are two types of topical calcineurin inhibitors called tacrolimus and pimecrolimus, and are recommended as the first-line treatments in vitiligo. Although pimecrolimus is efficacious for the repigmentation of vitiligo, its intrinsic mechanisms have never been investigated in vitro. This research aimed to study the ability of pimecrolimus on stimulating melanogenesis, melanocyte migration and MITF (microphthalmia associated transcription factor) protein expression. Results showed that pimecrolimus at the dosages of 1, 10, 102 nM were neither mitogenic nor cytotoxic to melanocytes. The addition of pimecrolimus at 10, 102 and 103 nM significantly increased intracellular tyrosinase activity, which was consistent with the elevated content of melanin content at the same concentrations. The peak effect was seen at 72 h in response to 102 nM pimecrolimus. Results of the wound scratch assay and Transwell assays indicate that pimecrolimus is effective in facilitating melanocyte migration on a collagen IV-coated surface. In addition, MITF protein yield reached the highest by pimecrolimus at 102 nM. In brief, pimecrolimus enhances melanin synthesis as well as promotes migration of melanocytes directly, possibly via their effects on MITF protein expression.

show abstract

Interventions for vitiligo

Cited by 115 publications

References 149 publications

Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo

Evaluation of treatment response to autologous transplantation of noncultured melanocyte/keratinocyte cell suspension in patients with stable vitiligo

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Pimecrolimus increases the melanogenesis and migration of melanocytes in vitro

Contact Info

Product

Resources

About